Please assess the completion status of the following clinical trial:

Trial Title: Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be either (1) at high risk for candidiasis (1 month - \< 2 years ONLY) or (2) have a definitive diagnosis of invasive candidiasis/candidemia (ICC) (All age groups)~* Male and female patients from 1 month to less than 18 years of age.~Exclusion Criteria:~* Any patients with allergy to the drug; and any pregnant female or lactating.~* Failed previous antifungal therapy or expected to live \< 3 days.~* Patients with documented or suspected Candida meningitis.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Anidulafungin IV (Type: EXPERIMENTAL): All subjects meeting screening criteria will receive IV anidulafungin.

Based on this trial design, predict the completion outcome and termination type (if applicable).